Troglitazone and metformin, but not glibenclamide, decrease blood pressure in Otsuka Long Evans Tokushima Fatty rats

Clinical and Experimental Hypertension

Volumn 21, Issue 3, 1999, Pages 199-211

  Kosegawa, Itaru ^a   Chen, Sufang ^a   Awata, Takuya ^a   Negishi, Kiyohiko ^a   Katayama, Shigehiro ^a  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Glibenclamide; Glucose transporter 4; Insulin resistance; Metformin; Otsuka Long Evans Tokushima Fatty rats; Troglitazone

Indexed keywords

GLIBENCLAMIDE; GLUCOSE TRANSPORTER; INSULIN; METFORMIN; TRIACYLGLYCEROL; TROGLITAZONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BLOOD PRESSURE REGULATION; DOSE RESPONSE; DRUG EFFECT; GLUCOSE BLOOD LEVEL; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; RAT; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0032910313     PISSN: 10641963     EISSN: None     Source Type: Journal    
DOI: 10.3109/10641969909068661     Document Type: Article

References (37)

1. DeFronzo R. A. Pathogenesis of NIDDM: A balanced overview. Diabetes Care 1992; 15: 318-368.
2. Granner D. K., O'Brien R. M. Molecular physiology and genetics of NIDDM: Importance of metabolic staging. Diabetes Care. 1992; 15: 369-395.
3. Lucus Cp, Estigarribia J. A., Darga L. L., Reaven G. M.: Insulin and blood pressure in obesity. Hypertension. 1985; 7: 702-706.
4. Singer P., Godicke W., Voigt S., Hajdu I., Weiss M. Postprandial hyperinsulinemia in patients with mild essential hypertension. Hypertension 1985; 7: 182-186.
5. Modan M., Halkin H., Almong S. Hyperinsulinemia: A link between hypertension, obesity and glucose intolerance. J Clin Invest. 1985; 75: 809-817.
6. Ferrannini E., Buzzigoli G., Bonadona R., Giorico M.A., Oleggini M., Graziadei L., Pedrinelli R., Bevilacqua S. Insulin resistance in essential hypertension. N Engl J Med 1987; 317: 350-357.
7. Shen D-C, Shieh S-M, Fuh MM-T, Wu D-A, Chen Y-DI, Reaven G. M. Resistance to insulin-stimulated glucose uptake in patients with hypertension. J Clin Endocrinol Metab 1988; 66: 580-583.
8. Perriello G., Misericordia P., Volpi E., Snatucci A., Santucci C., Ferraninni E., Ventura M., Santeusanio F., Brunetti P., Bolli G. Acute antihyperglycemic mechanisms of metformin in NIDDM: evidence for suppression of lipid oxidation and hepatic glucose production. Diabetes 1994; 43: 920-928.
9. Widen E. I. M., Eriksson J. G., Groop L. C. Metformin normalizes non-oxidative glucose metabolism in insulin-resistant normoglycemic first-degree relatives of patients with NIDDM. Diabetes 1992; 41: 354-358.
10. Fujiwara T., Yoshioka S., Yoshioka T., Ushiyama I., Horikoshi H. Characterization of new oral antidiabetic agent CS-045. Studies in KK and ob/ob mice and Zucker fatty rats. Diabetes 1988; 37: 1549-1558.
11. Iwamoto Y., Kuzuya T., Matsuda A., Awata T., Kumakura S., Inooka G., Shiraishi I. Effect of new oral antidiabetic agent CS-045 on glucose tolerance and insulin secretion in patients with NIDDM. Diabetes Care 1991; 14: 1083-1086.
12. Hofman C.A., Çolca J. R. New oral thiazolidinedione antidiabetic agents act as insulin sensitizers. Diabetes Care 1992; 15: 1075-1078.
13. Landin K., Tengborn L., Smith U. Treating insulin resistance in hypertension with metformin reduces both blood pressure and metabolic risk factors. J Intern Med 1991; 229: 181-187.
14. Giugliano D., Acampora R., DeRosa N., Buoninconti R., DiMaro G., D'Onofrio F., Marfella R. Metformin improves glucose, lipid metabolism, and reduces blood pressure in hypertensive, obese women. Diabetes Care 1993; 16: 1387-1390.
15. Kosegawa I., Katayama S., Kiuchi C., Kashiwabara H., Negishi K., Ishii J. Metformin decreases blood pressure and obesity in OLETF rats via improvement of insulin resistance. Hypertens Res 1996; 19: 37-41.
16. Nagi D.K., Yudkin J.S. Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. Diabetes Care 1993; 16: 621-629.
17. Dorella M., Giusto M., DaTos V., Campagnolo M., Palatini P., Rossi G., Ceolotto G., Felice M., Semplicin A., DelPrato S. Improvement of insulin sensitivity by metformin treatment does not lower blood pressure of nonobese insulin-resistant hypertensive patients with normal glucose tolerance. J Clin Endocrinol Metab 1996; 81: 1568-1574.
18. Yoshioka S., Nishino H., Shiraki T., Ikeda K., Koike H., Okuno A., Wada M., Fujiwara T., Horikoshi H. Antihypertensive effects of CÍ-045 treatment in obese Zucker rats. Metabolism 1993; 42: 75-80.
19. Chen S., Noguchi Y., Izumida T., Tatebe J., Katayama S. A comparison of the hypotensive and hypoglycemic actions of an angiotensin converting enzyme inhibitor, an AT1a antagonist and troglitazone. J Hypertens 1996; 14: 1325-1330.
20. Lee M-K, Miles P., Khoursheed M., Gao K., Moossa A.R., Olefsky J.M. Metabolic effects of troglitazone on fructose-induced insulin resistance in the rat. Diabetes 1994; 43: 1435-1439.
21. Pershadsingh H., Szollosi J, Benson S., Hyum W.C., Feuerstein B. G., Kurtz T. W. Effects of ciglitazone on blood pressure and intracellular calcium metabolism. Hypertension. 1993; 21: 1020-1023.
22. Kemnitz J. W., Elson D. F., Rocker E. B., Baum S. T., Bergman R. N., Meglasson M. D. Pioglitazone increases insulin sensitivity, reduces blood glucose, insulin and lipid levels and lowers blood pressure in obese insulin-resistant rhesus monkeys. Diabetes. 1994; 43: 204-211.
23. Katayama S., Abe M., Kashiwabara H., Kosegawa I., Ishii J. Evidence against a role of insulin in hypertension in spontaneously hypertensive rats. CS-045 does not lower blood pressure despite improvement of insulin resistance. Hypertension. 1994; 23 (part 2): 1071-1074.
24. Nolan J. J., Ludvik B., Beerdesen P., Joyce M., Olefsky J. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med. 1994; 331: 1188-1193.
25. Ogihara T., Rakugi H., Mikami H., Masuo K. Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives. Am J Hypertens. 1995; 8: 316-320.
26. Kawano K., Hirashima T., Mori S., Saitoh Y., Kurosumi M., Natori T. Spontaneous long-term hyperglycemic rat with diabetic complications. Otsuka Long-Evans Tokushima Fatty (OLETF) strain. Diabetes. 1992; 41: 1422-1428.
27. Lin J-L, Asano T., Ihibasaki Y., Tsukuda K., Katagiri H., Ishihara H., Takaku F., Oka Y. Altered expression of glucose transport isoforms with aging in rats. Selective decrease in Glut4 in the fat tissue and skeletal muscle. Diabetologia 1991; 34: 477-482.
28. Laemmli U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (Lond). 1970; 227:680-685.
29. Hundal H. S., Ramlal T., Reyes R., Leiter L. A., Klip A. Cellular mechanism of metformin action involves glucose transporter translocation from an intracellular pool to the plasma membrane in L6 muscle cells. Endocrinology. 1992; 131: 1165-1173.
30. Matthael S., Reibold J. P., Hamann A., Benecke H., Haring H. U., Greten H., Klein H. H. In vivo metformin treatment ameliorates insulin resistance. Evidence for potentiation of insulin-induced translocation and increased frunctional activity of glucose transporters in obese (fa/fa) Zucker rat adipocytes. Endocrinology. 1993; 133: 304-311.
31. Hofmann C., Lorenz K., Colca J. R. Glucose transport deficiency in diabetic animals is corrected by treatment with the oral antihyperglycemic agent pioglitazone. Endocrinology 1991; 129: 1915-1925.
32. Tsiani E., Ramlal T., Leiter L. A., Klip A., Fantus I. G. Stimulation of glucose uptake and increased plasma membrane content of glucose transporters in L6 skeletal muscle cells by the sulfonylureas gluclazide and glyburide. Endocrinology. 1995: 136: 2505-2512.
33. Vestergaard H., Weinreb J. E., Rosen A. S., Bjorbaek C., Hansen L., Pedersen O., Kahn B. B. Sulfonylurea therapy improves glucose disposal without changing skeletal muscle GLUT4 levels in non-insulin-dependent diabetes mellitus subjects: A longitudinal study. Endocrinology. 1995; 80: 270-275.
34. Schmitz O., Lund S., Orskov L., Anderson P. H., Meller N., Rasmussen O., Christensen J. S. Effects of glipizide on glucose metabolism and muscle content of the insulin-regulatable glucose transporter (GLUT4) and glycogen synthase activity during hyperglycaemia in type 2 diabetic patients. Acta Diabetologia. 1994; 31: 31-36.
35. Antomarchi S. H., Weille J. D., Fosset M., Lazdunski M. The receptor for antidiabetic sulfonylureas controls the activity of the ATP-modulated K channel in insulin-secreting cells. J Biol Çhem 1987; 262: 15840-15844.
36. Standen N. B., Quayle J. M., Davies N. W., Brayden J. E., Huang Y., Nelson M. T. Hyperpolarizing vasodilators activate ATP-sensitive K channels in arterial smooth muscle. Science Wash DC. 1985; 245: 177-180.
37. Imamura Y., Tomoike H., Narishige T., Takahashi T., Kasuya H., Takeshita A. Gibenclamide decreases basal coronary blood flow in anesthetized dogs. Am J Physiol. 1992; 263: H399-H404.